Nanopore technology enables the sustained release of drugs during several months from a small subcutaneous implant device.

SAN FRANCISCO, CA, June 23, 2011 – Delpor, Inc. (Delpor), a biotechnology company focused on drug delivery, today announced that the United States Patent and Trademark Office issued on June 7, 2011 U.S. Patent No. 7,955,614 covering Delpor’s microfabricated nanopore device for the sustained release of therapeutic agents. The device uses Delpor’s proprietary NANOPORTM technology for the sustained (zero-order) release of large and small molecules for several months after subcutaneous implantation. Delpor has exclusive rights to the patented technology and has several product candidates in development.

Numerous therapeutic agents including interferon-alpha, human growth hormone, and GLP-1 can benefit from long-term sustained delivery. The benefits of such delivery include improved safety, efficacy, medication adherence, as well as patient convenience in cases where frequent subcutaneous injections are required. Delpor’s unique technology is able to achieve steady (zero-order) release of agents for several months through passive diffusion (i.e., without using an osmotic pump, or any mechanical parts inside the device). A nanopore membrane, fabricated to include arrays of channels with precise geometry, is used to control the rate of diffusion and provide a zero-order rate of release of the substance.

“This patent is an important component of Delpor’s intellectual property portfolio” said Tassos Nicolaou, President and CEO of Delpor. “Our NANOPORTM technology may be used for the sustained long-term delivery of a variety of therapeutic agents while eliminating the need of using any mechanical parts inside the device. This allows tremendous formulation flexibility, simplifies the manufacturing process, and most importantly eliminates the safety risks associated with osmotic systems”

About Delpor, Inc.
Delpor develops the next generation Drug Delivery Systems that improve the clinical and commercial value of drugs and biopharmaceuticals. The company’s technologies enable the sustained release of drugs through a small non-mechanical subcutaneous implant device. The device is implanted during a 10 minute, simple, in-office, procedure using local anesthetic and without the need for any surgical sutures. Delpor’s device can deliver small & large molecules within a predefined therapeutic window over several months while maintaining zero-order release pharmacokinetics. Delpor is focusing on the delivery of antipsychotics (in order to improve medication adherence, tolerance, and safety) as well as biologics in order to improve patient safety and convenience. The company’s lead products include 3-month formulations of Risperidone, Paliperidone, and Interferon-alpha. Additional information about the company can be found at

Forward-Looking Statements
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future.

Delpor, Inc.
Tassos Nicolaou, President and CEO
Phone: 415-480-6873
Fax: 415-480-6871